

CURRICULUM VITAE
Celeste Nicola, PhD

Version date: 09/25/2025

Proposed for: Promotion to Postdoctoral Associate in the Department of Pathology,
Yale School of Medicine

Term: Primary Appointment: 11/01/2025

School: Yale School of Medicine

Education:

09/2013-06/2016 BS, Molecular Biology, University of Turin, Turin, Italy

09/2016-06/2019 MS, Neuroscience, University of Turin, Turin, Italy

09/2020-12/2023 PhD, Neuroimmunology, University of Rouen, Rouen, France

Career/Academic Appointments:

06/2019-08/2020 Research Associate, University of Rouen, Rouen, France

09/2024-10/2025 Postdoctoral Fellow in Neuroimmunology, University of Lyon, Lyon, France

Board Certification:

2013 Animal Experimentation Certification (EU Directive 2010/63, Functions A–D, equivalent FELASA Category C), VetAgro Sup – University of Lyon

Professional Honors & Recognition:

International/National/Regional

2023 Young Investigator Award, International Cognition and Cancer Task Force, San Diego, CA

2022 Best Presentation Award, Onconeurotox, Paris, France

2022 Best Presentation Award, Journées Normandes de la Recherche Biomédicale, Rouen, France

2022 Best Presentation Award, Cancéropôle Nord-Ouest, Deauville, France

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:

International/National

1. “Cognitive impairments and Immunotherapy”. University of Caen, Normandy. International Cognition and Cancer Task Force, 2025
2. “Cognitive deficits associated with peripheral cancer and Immunotherapy treatments.” International Cognition and Cancer Task Force, San Diego, CA. 2023
3. "Immunotherapy and cognition." Onconeurotox, Paris, France, 2022.

Bibliography:

Peer-Reviewed Original Research

1. **Nicola C**, Dubois M, Castel H. The prostate cancer therapy Enzalutamide compared with Abiraterone Acetate / Prednisone impacts motivation for exploration, spatial learning and alters dopaminergic transmission in aged castrated mice. *Cancers*, 202113(14):3518. PMID : 34298734, PMCID : PMC8304001, DOI : 10.3390/cancers13143518.
2. Pedard M, **Nicola C**, Castel H. The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male mice. *Nature*

Communications, 2024.15:8430. PMID : 39341842, PMCID : [PMC11439053](#), DOI : [10.1038/s41467-024-52654-2](#)

3. Lange M, **Nicola C**, Joly F. Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. BMC Cancer. 13;22(1):1308. PMID : 36513991, PMCID : [PMC9749352](#), DOI : [10.1186/s12885-022-10384-y](#).
4. Farina A, **Nicola C**, Desestret V. Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies. Therapeutic Advances in Neurological Disorders. Accepted, September 2025.

In Press: Peer-Reviewed Original Research In Press

1. **Nicola C**, Pedard M, Castel H. Anti-PD-1/PD-L1 Therapy Triggers Cognitive Deficits and Anxiety-Like Behaviors Through Tumor-Initiated Neuroinflammatory Niches in Male Mice. Preprint, Biorxiv 2025. DOI : 10.1101/2025.09.03.673981
2. **Nicola C**, Peter E, Desestret V. Vascular and mesenchymal signatures in breast cancers associated with Yo and Ri paraneoplastic syndrome. eBiomedicine (Submitted 2025).

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Joly F, **Nicola C**, Lange M. Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge. Journal of Clinical and Experimental Neuropsychology. PMID: 40323211, DOI: 10.1080/13803395.2025.2498713
2. Kuil L, **Nicola C**, Castel H. Neurotoxicity of chemotherapy and brain-radiotherapy in cancer: overlapping mechanisms underlying cognitive impairment. Journal of Clinical and Experimental Neuropsychology. PMID: 40784023, DOI: 10.1080/13803395.2025.2539199